Pfizer Initiates P-II/III (EPIC-PEDS) Trial of Paxlovid (nirmatrelvir) for the treatment of Pediatric Patients with COVID-19
Shots:
- The company has initiated the P-II/III (EPIC-PEDS) trial to evaluate the safety, PK, and efficacy of Paxlovid vs PBO in 140 pediatric patients aged ≤18yrs. with COVID-19
- The results from the (EPIC-HR) study showed a reduction in the risk of hospitalization or death from any cause by 89% within 3 days of symptom onset & 88% within 5 days of symptom onset in non-hospitalized, high-risk adults while no deaths were observed
- Additionally, the US FDA has issued a EUA for the emergency use of Paxlovid for the treatment of COVID-19 in adults and pediatric patients aged ≥12yrs. who are at high risk for progression to severe COVID-19 including hospitalization or death
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
